Company profile
Ticker
EPRX
Exchange
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Latest filings (excl ownership)
6-K
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
21 May 24
6-K
Annual General and Special Meeting
15 May 24
6-K
Current report (foreign)
14 May 24
6-K
Consolidated Financial Statements
8 May 24
6-K
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
2 May 24
6-K
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
11 Apr 24
6-K
Current report (foreign)
10 Apr 24
6-K
Material Change Report
8 Apr 24
6-K
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
8 Apr 24
S-8
Registration of securities for employees
5 Apr 24
Latest ownership filings
No filings
Financial summary
Quarter (USD) | Dec 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Annual (USD) | Dec 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Press releases
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
14 May 24
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
14 May 24
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
8 May 24
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
8 May 24
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
2 May 24